Delving into the Latest Updates on Anhui Kedgene Biological Science and Technology Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

T-lymphocyte cell therapy

Gene therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

T-lymphocyte cell therapy	2
Gene therapy	1

Top 5 Target	Count

PD-1(Programmed cell death protein 1)	1

主要目的：评价PD-1基因定制活化T细胞注射液用于治疗肝细胞癌患者的人体耐受性与安全性剂量范围，确定最大耐受剂量（MTD）和/或探索最佳生物学剂量（OBD）。次要目的： 1）测定PD-1基因定制活化T细胞注射液单次药代动力学参数； 2）评价PD-1基因定制活化T细胞注射液输注的药效学； 3）评价PD-1基因定制活化T细胞注射液治疗肝细胞癌患者的初步疗效。探索性目的：评估PD-1基因定制活化T细胞回输入自体后的生物标志物与疗效和不良反应之间的关系。

[Translation]

Main purpose: To evaluate the human tolerance and safety dose range of PD-1 gene customized activated T cell injection for the treatment of patients with hepatocellular carcinoma, determine the maximum tolerated dose (MTD) and/or explore the optimal biological dose (OBD). Secondary purpose: 1) Determine the single pharmacokinetic parameters of PD-1 gene customized activated T cell injection; 2) Evaluate the pharmacodynamics of PD-1 gene customized activated T cell injection infusion; 3) Evaluate the preliminary efficacy of PD-1 gene customized activated T cell injection in the treatment of patients with hepatocellular carcinoma. Exploratory purpose: To evaluate the relationship between biomarkers and efficacy and adverse reactions after PD-1 gene customized activated T cells are reintroduced into the autologous body.

Start Date18 Jul 2024

Sponsor / Collaborator

Anhui Kedgene Biological Science and Technology Co., Ltd.

100 Clinical Results associated with Anhui Kedgene Biological Science and Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Anhui Kedgene Biological Science and Technology Co., Ltd.

Login to view more data

100 Deals associated with Anhui Kedgene Biological Science and Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Anhui Kedgene Biological Science and Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

PD-1 knockout engineered T cells(Anhui Korton Biological Technology Co Ltd)	Esophageal Carcinoma More	Phase 2
PD-1 targeted T cell (Anhui Korton) ( PD-1 )	Advanced Hepatocellular Carcinoma More	Phase 1